<?xml version="1.0"?><?xml-stylesheet type="text/xsl" href="drug-table.xslt"?><drug name = "pentamidine inj VIAL">
<dose><value>4</value>
<value>300</value>
<value>2 - 4</value>
</dose>
<route><value>IV </value>
<value>IV</value>
<value>INH</value>
<value>IM</value>
</route>
<strength><value>300 mg</value>
</strength>
<frequency><value>DAILY</value>
<value>MONTHLY</value>
<value>EVERY 4 WEEKS</value>
<value>EVERY 2 WEEKS</value>
<value>EVERY 3 WEEKS</value>
<value>WEEKLY</value>
<value>TWO TIMES WEEKLY</value>
</frequency>
<instruction><value>Administer by Respirgard II nebulizer.</value>
</instruction>
<volume></volume>
<units><value>mg/kg</value>
<value>mg</value>
</units>
<Population><value>ADULT. Treatment of Pneumocystis jiroveci.</value>
<value>ADULT. Prophylaxis of Pneumocystis jiroveci.</value>
<value>CHILDREN. Treatment of Pneumocystis jiroveci.</value>
<value>CHILDREN. Prophylaxis of Pneumocystis jiroveci.</value>
<value>ADULT. Leishmaniasis, visceral</value>
<value>ADULT. Leishmaniasis, cutaneous</value>
</Population>
<IndicationPRN></IndicationPRN>
<AdditionalNotes><value>Recommended treamtment is 14 days. Benefits and risks of treament for longer than 14 days are not well defined.</value>
<value>Recommend treatment until lesions heal.</value>
</AdditionalNotes>
<BackgroundInformation></BackgroundInformation>
<PRNInformation></PRNInformation>
<AHSFormularyStatus></AHSFormularyStatus>
<HighAlert></HighAlert>
</drug>